CDC's Advisory Committee for Immunization Practices (ACIP) Considers Expanding Recommendations for Human Papilloma Virus (HPV) Vaccine to Include Ages 27 to 45

WASHINGTON, Feb. 26, 2019 /PRNewswire/ -- CDC's ACIP committee will consider recommending the HPV vaccine to men and women ages 27 to 45. This recommendation would potentially expose over 80 million adults to the Gardasil 9 vaccine. Robert F. Kennedy, Jr. sent a letter to Chairman Jose R. Romero and ACIP members on February 25^th, on behalf of Children's Health Defense (CHD) voicing safety concerns.

Kennedy states that CHD considers an expansion of the HPV recommendations reckless and outlined numerous reasons to support his concerns. These include the fact that during Gardasil's clinical trials an extraordinary 49.5% of the subjects receiving Gardasil reported serious medical conditions within seven months of the start of the clinical trials. Because Merck did not use a true inert placebo in its clinical trials, but instead aluminum, its researchers were able to dismiss the trial participants' injuries as coincidences, employing the term "new medical conditions," rather than classifying their injuries as "adverse events."

HPV vaccines have been reported to cause death and serious injuries in the children and young adults at a rate higher than for any other ACIP-recommended vaccine. Since 2006, when Gardasil came on the U.S. market, over 450 deaths and over 61,000 serious medical conditions from HPV vaccines have been reported to the government's Vaccine Adverse Event Reporting System (VAERS). While these numbers reflecting reported vaccine injuries are startling, they likely only represent a fraction of injuries. A government funded study established that the voluntary VAERS system captures less than 1% of vaccine injuries and deaths.

In September, CHD released an ordered stipulation from Health and Human Services (HHS) proving they were not in compliance with statutory requirements for childhood vaccine safety reviews and reports to Congress. Earlier this month, in a similar ruling, FDA admitted that they had no records of clinical trials relied upon to approve any currently licensed influenza or Tdap vaccines recommended during pregnancy.

Kennedy's letter informs Romero that CHD will seek to hold ACIP members supporting the recommendation accountable for endangering the targeted population with a product that has little proven efficacy and could put recipients at higher risk of developing cancer and other grave health conditions.

Media Contact:
Laura Bono
202-854-1310
[email protected]

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Lyn Redwood
ProfNet - https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=129376

Robert Kennedy
ProfNet - https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=129377

Mary Holland
ProfNet - https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=129378

SOURCE Children's Health Defense

Related Links

http://www.childrenshealthdefense.org